Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?

Clin Infect Dis. 2017 Nov 29;65(12):2137-2143. doi: 10.1093/cid/cix675.

Abstract

Early administration of appropriate empiric antibiotics is essential for achieving the best possible outcomes in sepsis. Yet the choice of antibiotic therapy has become more challenging due to recent reports of nephrotoxicity with the combination of vancomycin and piperacillin/tazobactam, the "workhorse" regimen at many institutions. In this article we assess the evidence for nephrotoxicity and its possible mechanisms, provide recommendations for risk mitigation, address the advantages and disadvantages of alternative antibiotic choices, and suggest areas for future research.

Keywords: Sepsis; nephrotoxicity; piperacillin/tazobactam; vancomycin.

MeSH terms

  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / adverse effects*
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Bacterial Agents / toxicity*
  • Combined Modality Therapy / adverse effects*
  • Drug Therapy, Combination / adverse effects*
  • Humans
  • Kidney / drug effects*
  • Kidney / pathology
  • Kidney Diseases / chemically induced*
  • Penicillanic Acid / administration & dosage
  • Penicillanic Acid / adverse effects
  • Penicillanic Acid / analogs & derivatives
  • Penicillanic Acid / therapeutic use
  • Penicillanic Acid / toxicity
  • Piperacillin / administration & dosage
  • Piperacillin / adverse effects
  • Piperacillin / therapeutic use
  • Piperacillin / toxicity
  • Piperacillin, Tazobactam Drug Combination
  • Sepsis / drug therapy
  • Vancomycin / administration & dosage
  • Vancomycin / adverse effects
  • Vancomycin / therapeutic use
  • Vancomycin / toxicity

Substances

  • Anti-Bacterial Agents
  • Piperacillin, Tazobactam Drug Combination
  • Vancomycin
  • Penicillanic Acid
  • Piperacillin